Trust the Power of
EYLEA—Proven Results
Across All
Approved
Indications1,2

eylea product

EYLEA efficacy and safety is backed by 8 pivotal studies evaluating clinical outcomes in over 3000 patients: VIEW 1 and VIEW 2 (Neovascular [Wet] AMD) at 52 and 96 weeks; VISTA and VIVID (DME and DR in patients with DME) at 52 and 100 weeks; PANORAMA (DR) at 24, 52, and 100 weeks; GALILEO and COPERNICUS (MEfCRVO) at 24 weeks; and VIBRANT (MEfBRVO) at 24 weeks.1,2 When starting a patient on EYLEA, consider the body of evidence demonstrating proven results.

EYLEA® (aflibercept) pre-filled syringe and packaging.

Empower your EYLEA
treatment decisions
from the start with
RESULTS
from the 8
pivotal clinical trials1

EYLEA4U®, Logo EYLEA® (aflibercept) Injection copay card EYLEA® (aflibercept) Injection copay card

Comprehensive Support
for Your Patients

From ensuring your eligible patients have access to EYLEA, to helping them
navigate the reimbursement, and even guiding you through orders, returns,
and more, we’re here to help.

In my eyes by Regeneron, Logo

Experience what
certain retinal diseases
can be like
in virtual
reality

A powerful teaching tool to use with your patients and caregivers, this unique app
lets the user experience symptoms of degenerative eye disease, such as diabetic
retinal changes, firsthand in a 360° view. In My Eyes uses virtual reality and
augmented reality to show the impact of vision impairment on everyday situations.

In my Eyes by Regeneron app  showing retinal disease through virtual reality
  • Download on the Apple App Store, Logo
  • Get it on Google Play, Logo

A powerful teaching tool to use with your patients and caregivers, this unique app lets the user experience symptoms of degenerative eye disease, such as diabetic retinal changes, firsthand in a 360° view. In My Eyes uses virtual reality and augmented reality to show the impact of vision impairment on everyday situations.

References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. March 2021.
  2. Wykoff CC. Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 2-Year Outcomes of the Phase 3 PANORAMA Study. Data presented
    at: Angiogenesis, Exudation and Degeneration Annual Meeting; February 8, 2020; Miami, FL.